One in five adults said they experienced any symptoms of anxiety or depression in a 2-week period, according to a 2022 CDC ...

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended ...

An esketamine-based nasal spray antidepressant for adults is under review in the US following a filing from Johnson & Johnson's pharma unit. Janssen has submitted a filing for esketamine to the US ...

Janssen, which is Johnson & Johnson’s pharma unit, submitted a filing to the European Medicines Agency for esketamine nasal spray, which is designed to help people with treatment-resistant ...

The FDA updated a warning on the label of esketamine nasal spray (Spravato) about the long-term cognitive and memory impairments that have been reported with ketamine misuse or abuse. New 3-year ...

Results, published in CNS Spectrums, showed a significant improvement in symptoms for those taking a new OAD with esketamine ...

In addition, half were given ketamine in the form of esketamine (part of the ketamine molecule) in a nasal spray and half were given a placebo. The study found those using esketamine had a much ...

"A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with ...

Presentations include new data supporting the safety and efficacy of SPRAVATO® (esketamine) CIII nasal spray and the Company's innovative portfolio of long-acting injectables (LAIs) for ...